Payment overview · 2025
General Payments
$11,268.62
82 reported records · 12 companies
Healthcare provider profile · identity verified
Sandra Schuldheisz, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · SOMERSET, KY · NPI 1194798934
Verified facts
What the public records show
CMS Open Payments records show Sandra Schuldheisz, MD received $11,268.62 in general payments during 2025 across 82 reported records.
Viatris Specialty LLC accounted for 86.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Yupelri.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tudorza Pressair by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 603 claims for Trelegy Ellipta by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYREM as an associated drug or biological on 613 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyrem by this doctor in 2024.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported YUPELRI as an associated drug or biological on 26927 records involving 11152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Yupelri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $9,755.98 | 86.6% | 32 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $566.22 | 5.0% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $184.55 | 1.6% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.54 | 1.4% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $133.32 | 1.2% | 6 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $114.11 | 1.0% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $105.77 | 0.9% | 5 | 2025 |
| ERBE USA Inc | Unresolved — no canonical attribution shown | $100.00 | 0.9% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $78.45 | 0.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.71 | 0.3% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.18 | 0.2% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $13.79 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,273.75 | 4 |
| Food and Beverage | $1,751.60 | 73 |
| Travel and Lodging | $1,243.27 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $9,755.98 | 32 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $566.22 | 11 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $282.51 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $133.40 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $133.32 | 6 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $114.11 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $111.52 | 2 | 2025 |
Source payment records
|
|||||
| ErbeCryo2 Normalized: erbecryo2 |
Device | ERBE USA Inc | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $78.45 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 603 | exact normalized | Medicare Part D |
| YUPELRI yupelri |
2025 | Yupelri | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
603 | 144 |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYREM open payments reported associated product |
CMS Open Payments — General Payments 613 supporting records · 589 recipient NPIs · example record 1234298066 |
Xyrem · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | YUPELRI open payments reported associated product |
CMS Open Payments — General Payments 26927 supporting records · 11152 recipient NPIs · example record 1238463489 |
Yupelri · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 603 | 144 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 442 | 148 |
| Prednisone | Prednisone | 311 | 171 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 293 | 70 |
| Roflumilast | Roflumilast | 244 | 50 |
| Breo Ellipta | Fluticasone/Vilanterol | 192 | 35 |
| Montelukast Sodium | Montelukast Sodium | 158 | 33 |
| Ventolin Hfa | Albuterol Sulfate | 148 | 44 |
| Spiriva Respimat | Tiotropium Bromide | 131 | 33 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 129 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 126 | 104 |
| Clonazepam | Clonazepam | 122 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 105 | 24 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 98 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 97 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 73 |
| Incruse Ellipta | Umeclidinium Bromide | 86 | 22 |
| Azithromycin | Azithromycin | 78 | 31 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 73 | 17 |
| Belsomra | Suvorexant | 69 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 67 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 43 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 12 |
| Armodafinil | Armodafinil | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 13 |
| Theophylline Er | Theophylline Anhydrous | 33 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Dulera | Mometasone/Formoterol | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 12 |
| Tudorza Pressair | Aclidinium Bromide | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Quviviq | Daridorexant Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Rifampin | Rifampin | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Yupelri | Revefenacin | 14 | suppressed |
| Zafirlukast | Zafirlukast | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Provigil | Modafinil | 13 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Wakix | Pitolisant Hcl | 12 | suppressed |
| Xyrem | Sodium Oxybate | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Sunosi | Solriamfetol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,268.62 · 82 records | Viatris Specialty LLC | AIRSUPRA, BREZTRI, Da Vinci Surgical System, ErbeCryo2, Hillrom - Vest System Model 105 Home Care, INSPIRE, NUZYRA, Ohtuvayre, Prolastin-C Liquid, TEZSPIRE, TRELEGY ELLIPTA, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error